Agency: European Commission | Branch: FP7 | Program: CSA-SA | Phase: REGPOT-2009-2 | Award Amount: 995.50K | Year: 2010
INTRODUCTION. RAMSES comprises partner institutions from Germany (FMC), Romania (ICBP) and Egypt (CU) in order to promote closer S&T cooperation opportunities between Europe and Egypt. The concept of RAMSES is to build capacities by improving scientific relationships, networking and development of the S&T Human Potential, exchanging of know-how and experience between the participating partners, as well as by upgrading the S&T research capacities of CU. RAMSES partners will channel their expertise to complete the proposed objectives by 6 highly interlinked work packages. OBJECTIVES. Exchange of scientific know-how and experience will be implemented primarily via trans-national secondments of research staff. Reinforcement of human resources and infrastructures will focus on the increase of research quality, visibility and competitiveness of CU. Workshops, conferences and training events for knowledge sharing network building will facilitate knowledge transfer at national & international level. Hands-on, Advanced, and Multiplier workshops will allow a robust transfer and sharing of acquired skills & experience. Dissemination and promotional activities will provide maximum support for management, dissemination, promotion, and exploitation of project outcomes. Evaluation will monitor RAMSES progress to ensure its structured implementation. Consortium management & assessment of progress and results will aim at implementing strong management structures in order to coordinate the different activities. RELEVANCE. Through these objectives, RAMSES will establish networking conditions that will allow the promising CU the opportunity to develop a partnership through twinning actions with EU Centers of Excellence and to realize its full research potential. These shall contribute to regional development, while taking advantage of the knowledge and experience existing in other regions of Europe. Hence RAMSES will help to fully realize the European Research Area.
Agency: European Commission | Branch: FP7 | Program: MC-IRG | Phase: PEOPLE-2007-4-3.IRG | Award Amount: 50.00K | Year: 2008
Introduction: Transdifferentiation of umbilical cord (UC) blood, bone marrow (BM) and vessel derived stem cells into endothelial progenitors has been reported both in vitro and in vivo. Encouraging but limited success with these studies suggested the need for identification of more versatile populations of endothelial progenitors or signaling pathways to improve their homing to ischemic sites seeking angiogenesis and neovascularization. Objective: We propose to isolate and characterize in vitro endothelial progenitors derived from BM, placental vessels, and UC blood/matrix and to investigate whether successful in vivo endothelial regeneration, differentiation and maintenance can be achieved by systemic delivery when a defined demand is placed on the endothelium. Next, we propose to investigate whether endothelial progenitors homing to ischemic sites can be enhanced by delivery of chemoatractant molecules into the ischemic bed. Materials and methods: BM, placental vessel, and UC blood/matrix derived stem cell subpopulations will be assessed in clonal growth assays under conditions that promote endothelial commitment, and molecularly characterized for the expression of molecules and genes associated with endothelial lineage. The capacity of these cells to participate in vascular regeneration will be examined following systemic delivery into immunodeficient NOD/SCID mice with experimentally induced cardiac ischemia. Various chemokines will be investigated for their ability to augment endothelial progenitors homing to ischemic sites and to promote endothelial regeneration. Endothelial progenitors contribution to vascular reconstitution will be assessed by histology, immunohistochemistry, electron microscopy and clonal analyses of ischemic tissue samples. Relevance: The proposed study will bring new insights into stem cell research field, advancing the development of cell therapies for vascular regeneration relying on angiogenesis and neovascularization.